Skip to main content

Table 2 Base case results for EVE plus EXE vs. BEV plus PACL and BEV plus CAPE for the treatment of ER+ mBC patients

From: Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

     Incremental analysis
Outcomes EVE plus EXE BEV plus PACL BEV plus CAPE BEV plus PACL BEV plus CAPE
Treatment and administration costs* 25,727 € 32,960 € 25,832 € −7,233 € −105 €
AE costs (grade 3/4)* 62 € 5 € 1 € 57 € 61 €
Pre-progression background costs* 1,000 € 3,744 € 3,946 € −2,744 € −2,946 €
Post-progression background costs* 27,495 € 30,534 € 32,308 € −3,039 € −4,813€
Terminal care costs* 737.51 € 736.41 € 734,77 € 1.10 € −2.74 €
Total costs* 55,022 € 67,980 € 62,822 € −12,958 € −7,800 €
QALYS*: Pre-progressed 0.648 0.494 0.456 0.154 0.192
QALYS*: Post-progressed 1.076 1.195 1,264 −0.119 −0.188
Total QALYS* 1.724 1.689 1,720 0.035 0.004
Life years†: Pre-progressed 0.899 0.689 0.604 0.210 0.295
Life years†: Post-progressed 2.422 2.679 2.833 −0.257 −0.411
Total undiscounted life years† 3.321 3.368 3.437 −0.047 −0.116
Life years*: Pre-progressed 0.876 0.675 0.594 0.201 0.282
Life years*: Post-progressed 2.167 2.406 2.546 −0.240 −0.379
Total discounted life years* 3.043 3.082 3.140 −0.039 −0.097
Incremental cost per QALY     Dominant Dominant
Incremental cost per LY     Less effective Dominant
*discounted †undiscounted      
  1. EVE: everolimus; EXE: exemestane; BEV: bevacizumab; PACL: paclitaxel; CAPE: capecitabine; QALY: quality-adjusted-life years; mBC: metastatic breast cancer; LY: life year
\